What side effects are associated with this type of intervention?

Common treatments for breast cancer, especially targeted therapies like those studied in the AZD8205 trial, often include agents such as trastuzumab and capivasertib. The known side effects of these treatments can include diarrhea, fatigue, stomatitis, and cardiovascular issues. Additionally, chemotherapy agents like paclitaxel, often used in combination with targeted therapies, can cause neuropathy, myelosuppression, alopecia, and gastrointestinal disturbances. It is important for patients to discuss these potential side effects with their healthcare provider to manage and mitigate them effectively.

What prior FDA approvals exist?

Several targeted therapies have been approved by the FDA for the treatment of breast cancer. HER2 inhibitors such as trastuzumab, pertuzumab, and ado-trastuzumab emtansine target the HER2 protein, which promotes the growth of cancer cells. CDK4/6 inhibitors like palbociclib, ribociclib, and abemaciclib interfere with proteins that drive cell division. Additionally, PI3K inhibitors such as alpelisib target the PI3K pathway, which is involved in cell growth and survival. These therapies are designed to specifically target and inhibit pathways critical to tumor growth and metastasis, similar to the investigational agent AZD8205.

What other types of research exist?

Promising novel alternatives to AZD8205 for breast cancer patients in 2024 include: 1) Trastuzumab Deruxtecan (Enhertu), an antibody-drug conjugate targeting HER2-positive breast cancer. 2) Sacituzumab Govitecan (Trodelvy), an antibody-drug conjugate targeting Trop-2 in triple-negative breast cancer. 3) Alpelisib (Piqray), a PI3K inhibitor for HR-positive, HER2-negative breast cancer with PIK3CA mutations. 4) Pembrolizumab (Keytruda), an immune checkpoint inhibitor for PD-L1 positive breast cancer. These therapies have shown significant efficacy in clinical trials and are considered promising for future treatment options.

← Back to Search

Unknown

AZD8205 for Endometrial Cancer

Phase 1 & 2

Recruiting

Research Sponsored by AstraZeneca

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Eastern Cooperative Oncology Group (ECOG) Performance Status: 0-1

Age ≥ 18 years

Timeline

Screening 3 weeks

Treatment Varies

Follow Up from first dose of azd8205 to death ( approx. 2 years )

Awards & highlights

Study Summary

This trial is testing a new drug, AZD8205, to see if it can shrink or slow the growth of certain types of cancer.

Who is the study for?

Adults (18+) with advanced or metastatic solid tumors, specifically breast cancer, ovarian cancer, bile duct cancer (cholangiocarcinoma), or endometrial cancer. Participants must have measurable disease and an ECOG performance status of 0-1. They should expect to live at least 12 weeks and have proper organ/marrow function. Prior treatments vary by sub-study group.Check my eligibility

What is being tested?

The trial is testing AZD8205 for patients with certain types of advanced cancers that have spread beyond the original site. It's a first-in-human study to see if this new compound can be effective in treating these conditions.See study design

What are the potential side effects?

While specific side effects for AZD8205 are not listed here, common ones for similar drugs include nausea, fatigue, risk of infection due to low blood cell counts, liver issues, and potential allergic reactions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I can carry out all my daily activities without help.

Select...

I am 18 years old or older.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ from first dose of azd8205 to death ( approx. 2 years )

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~from first dose of azd8205 to death ( approx. 2 years )

This trial's timeline: 3 weeks for screening, Varies for treatment, and from first dose of azd8205 to death ( approx. 2 years ) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

The number of patients with adverse events

The number of patients with changes from baseline laboratory findings, ECGs and vital signs

The number of patients with dose-limiting toxicity (DLT), as defined in the protocol.

+1 more

Secondary outcome measures

Disease Control Rate at 12 weeks (DCR-12)

Duration of response (DoR)

Immunogenicity of AZD8205.

+8 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: Sub-Study 1 AZD8205 MonotherapyExperimental Treatment1 Intervention

Sub-Study 1 has two parts: Part A : The aim is to determine the safety, tolerability, Recommended Phase 2 Dose(RP2D), and/or the Maximum Tolerated Dose (MTD) of AZD8205. Part B: The aim of dose expansion is to evaluate anti-tumor activity of AZD8205 as monotherapy in select solid tumors.

0 / 2Eligibility criteria met

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.

Mechanism Of Action

Side Effect Profile

Prior Approvals

Other Research

Targeted therapies for breast cancer, such as those being studied in the trial AZD8205, work by inhibiting specific molecular pathways that are crucial for tumor growth and metastasis. These therapies often target proteins or genes that are overexpressed or mutated in cancer cells, such as HER2, CDK4/6, and mTOR. By blocking these pathways, targeted therapies can effectively slow down or stop the proliferation of cancer cells while minimizing damage to normal cells. This precision in treatment is particularly important for breast cancer patients as it can lead to better outcomes, fewer side effects, and a higher quality of life compared to traditional chemotherapy.

Breast Cancer Resistance to Cyclin-Dependent Kinases 4/6 Inhibitors: Intricacy of the Molecular Mechanisms.Pharmacokinetics, clinical indications, and resistance mechanisms in molecular targeted therapies in cancer.The emergence of targeted drugs in breast cancer to prevent resistance to endocrine treatment and chemotherapy.